Signios Biosciences

Executive Summary

Signios Biosciences is a US-based multiomics service provider headquartered in San Diego, with a scientist-led laboratory in Foster City, California. Founded in 2020, the company offers end-to-end next-generation sequencing (NGS) and proteomics services, integrated with bioinformatics and data analysis, to support precision medicine and therapeutic development. Its client base includes academic institutions, biopharmaceutical companies, clinical laboratories, and contract research organizations. By providing a comprehensive service from project design through data interpretation, Signios positions itself as a partner in accelerating research and development. The company operates in the growing multiomics and diagnostics market, leveraging its expertise to serve the expanding needs of precision medicine. While still in its early stages with limited public information on funding or valuation, Signios has established operational capabilities and a clear value proposition. Its focus on scientist-led, high-quality services differentiates it in the competitive CRO space.

Upcoming Catalysts (preview)

• Q1 2027Launch of Integrated Multiomics Platform60% success
• H2 2026Strategic Partnership with Major Pharma35% success
• Q3 2026Series A Funding Round Closure50% success